Advertisement
Canada markets open in 2 hours 5 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7317
    +0.0019 (+0.27%)
     

  • CRUDE OIL

    82.95
    +0.14 (+0.17%)
     

  • Bitcoin CAD

    87,207.72
    -3,546.42 (-3.91%)
     

  • CMC Crypto 200

    1,351.77
    -30.81 (-2.23%)
     

  • GOLD FUTURES

    2,341.30
    +2.90 (+0.12%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,486.25
    -178.25 (-1.01%)
     

  • VOLATILITY

    16.28
    +0.31 (+1.94%)
     

  • FTSE

    8,088.68
    +48.30 (+0.60%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Company News for Jan 12, 2022

Zacks Equity Research
·1 min read

  • Shares of Accolade, Inc. ACCD soared 27.7% after the company reported third-quarter fiscal 2021 revenues of $83.45 million, surpassing the Zacks Consensus Estimate.

  • Pacific Biosciences of California, Inc.’s PACB shares declined 11.3% after the company lowered its fourth-quarter fiscal 2021 sales guidance.

  • Shares of Big Lots, Inc. BIG declined 1.5% after the company said that it has lately witnessed softening of sales trends and traffic this month due to extreme cold weather and surge in Omicron cases.

  • Illumina, Inc.’s ILMN shares jumped 17% after the company raised its 2022 revenue outlook on strong demand for its gene sequencing treatments and four new partnerships with different health care companies.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Illumina, Inc. (ILMN) : Free Stock Analysis Report
 
Big Lots, Inc. (BIG) : Free Stock Analysis Report
 
Pacific Biosciences of California, Inc. (PACB) : Free Stock Analysis Report
 
Accolade, Inc. (ACCD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research